Published in:
Open Access
01-05-2014 | ePoster presentation
Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection
Authors:
Rupesh V Chikhale, Amit M Pant, Sunil S Menghani, Pramod B Khedekar
Published in:
BMC Infectious Diseases
|
Special Issue 3/2014
Login to get access
Excerpt
The emerging multidrug resistant (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) infection is increasing with greater complexity, estimated 220000-400000 tuberculosis cases emerged in 2011 globally. A number of lead compounds have been developed for treatment of MDR and XDR TB, but no new chemical entity has emerged for clinical use. Recently DprE1 and AHAS have been identified as promising drug targets. …